RecruitingNot ApplicableNCT05503966

Combining Antidepressants and Attention Bias Modification in Depression

Combining Antidepressants and Attention Bias Modification in Depression: a Randomized Controlled Trial in Primary Care


Sponsor

University of Oslo

Enrollment

246 participants

Start Date

Sep 22, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Background: Major depressive disorder (MDD) is a highly prevalent psychiatric condition associated with significant disability, mortality and economic burden. A large proportion of MDD patients are treated in primary health care (PHC) in the municipalities and represent a challenging group. Attentional Bias Modification (ABM) training in combination with antidepressants (SSRIs) could be an effective treatment. The overall aim of this study is to test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in PHC will result in further improvement of symptoms compared to treatment with antidepressants alone (treatment as usual, TAU) and as compared to an active comparison condition. Methods: A total of 246 patients with a diagnosis of MDD will be included in this study. The study is a three-armed pragmatic randomized controlled trial comparing the efficacy of ABM as add-on to treatment with antidepressants in primary care (ABM condition) compared to standard antidepressant treatment (TAU condition). In a third group participants will complete the same schedule of intermediate assessments as the ABM condition in addition to TAU , but no ABM, thus controlling for the non-training-specific aspects of the ABM condition (SSRI Active comparison group). Discussion: The clinical outcome of this study may help develop easy accessible, low cost treatment of depression in PHC. Moreover, the study aims to broaden our knowledge of optimal treatment for patients with a MDD by providing adjunct treatment to facilitate recovery and long term gain


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination approach to treating depression: standard antidepressant medication plus a computer-based training program called Attention Bias Modification (ABM). ABM trains the brain to shift attention away from negative stimuli, which may complement medication treatment. **You may be eligible if...** - You are between 18 and 65 and have been diagnosed with major depressive disorder - Your depression score on the BDI-II questionnaire is above 14 - You speak a Scandinavian language **You may NOT be eligible if...** - You have a history of neurological illness or traumatic brain injury - You have an active alcohol or substance use disorder - You have psychosis, bipolar disorder type 1, or a developmental disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALAttentional Bias Modification

The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.


Locations(1)

Jan Ivar Røssberg

Oslo, Nydalen, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05503966


Related Trials